Endogenous Hypercortisolism

Among patients with endogenous hypercortisolism, relacorilant improved cardiometabolic parameters such as blood pressure, HbA1c and weight, according to results of a long-term extension study.

A selective cortisol modulator was linked to lower odds for loss of blood pressure control among adults with Cushing’s syndrome compared with placebo, according to topline results from a phase 3 trial.